{'fraction_non_alphanumeric': 0.028192371475953566, 'fraction_numerical': 0.0, 'mean_word_length': 5.494623655913978, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Epidermal growth factor receptor (EGF) in head-and-neck cancers].

EGFR is frequently overexpressed and is associated with a poor prognosis in head and neck carcinoma (HNC). Among the biological and cellular effects resulting from EGFR targeting, there are the possibilities to restore apoptotic capacities and to reduce DNA-repair activity, to inhibit angiogenesis and tumor cell migration. This suggests the potential interest of the combination between anti-EGFR drugs and cytotoxic agents, especially ionizing radiation with promising results obtained at the clinical level in locally advanced HNC.